FOR IMMEDIATE RELEASE: Seattle | Dec. 19, 2018:
Gerry McDougall, a Senior Partner at PricewaterhouseCoopers Health Sciences Practice who serves as the company’s Global Health Science Practice Leader, has joined the Board of Directors of IDRI (Infectious Disease Research Institute). In his role at PwC, McDougall provides services to academic medical centers, bioscience companies, pharmaceutical companies, research universities, colleges, health systems and other research organizations.
“As IDRI celebrates its 25th anniversary this year, our sights turn to how to best position ourselves for the future,” said Steve Reed, Ph.D., IDRI President, CEO and Founder. “Having a strong, dynamic board that can help us create new partnerships and diversify our funding sources is key to future success, and Gerry has a wealth of knowledge in that arena. We’re pleased to welcome him to the IDRI Board of Directors as we launch new initiatives, including a focus on global oncology.”
McDougall brings experience in a broad range of research business and compliance services, including strategic and business planning, financial analysis, research compliance, clinical research operations improvement, and information systems implementation services. He specializes in the development of partnerships and creation of new research ventures.
Over the last decade of McDougall’s leadership of PwC’s Health Sciences practice, clients have included scientific leaders, boards of directors, leaders of patient advocacy groups, the U.S. government and governors of several states. In the past five years, McDougall and his teams have helped secure billions of dollars for biomedical research and he has been instrumental in assisting organizations in developing strategies and plans to invest funds for the early detection of cancer.
“In the last two decades plus I have never been more excited about the possibility of making a scale impact in oncology in the developing world,” said McDougall. “Based on IDRI’s track record of success in vaccines and world class science, I believe the organization is positioned to make a transformative impact in oncology vaccines that will benefit patients around the world and perhaps save tens of millions of lives in developing world. I couldn’t be more honored to join the board of this incredible organization and a group of scientists to help in any way possible to carry out and accomplish the mission.”
In addition to joining IDRI’s Board of Directors, McDougall serves on a number of other boards including the Multiple Myeloma Research Foundation, Conquer Cancer Foundation and Curable.
About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
Contact: Lee Schoentrup | email@example.com